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Abstract : Background : CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) is the master regula-
tor of programmed cell death-ligand 1 (PD-L1). We aimed to clarify the significance of CMTM6 expression in gas-
tric cancer (GC). Methods : A total of 105 patients who had undergone curative surgical resection for stage II / III 
GC at Tokushima University Hospital were included in this study. The expression of CMTM6 was examined by 
immunohistochemistry. Additionally, the relationship of each expression level to several prognostic factors was 
examined using univariate and multivariate analyses. Results : CMTM6 was not positively correlated with any 
of the factors examined. The overall survival (OS) rates were significantly poorer in the CMTM6 high-expression 
group than in the CMTM low-expression group (5-year OS : 57.2% vs. 79.2%, respectively ; p < 0.05). Disease-free 
survival (DFS) was significantly poorer in the CMTM high-expression group than in the CMTM6 low-expression 
group (5-year DFS : 52.8% vs. 72.4%, respectively ; p < 0.05). Multivariate analysis confirmed CMTM6 expression 
as an independent prognostic factor in DFS (p < 0.05). CMTM6 expression tended to be correlated with PD-L1 
expression (p = 0.07). Conclusions : CMTM6 is associated with a poor prognosis and immunotolerance through 
PD-L1 in GC.  J. Med. Invest. 68 : 362-367, August, 2021
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BACKGROUND
 
Recent refinements in the investigation of tumor immunity 
and tumor microenvironments have led to an increasing number 
of advanced cancer treatments. Since the advent of the clinical 
use of immune-checkpoint inhibitors, the treatment strategies 
for advanced solid tumors have been changing. Blockade of the 
programmed cell death protein 1 (PD-1) / PD-L1 : programmed 
cell death-ligand 1 (PD-L1) interaction is crucial to the inhibitory 
axis in the suppression of tumor-specific T-cell responses. We 
previously reported that PD-1 and PD-L1 expression are sig-
nificant prognostic factors in gastric cancer (GC) patients after 
curative resection (1).
CKLF-like MARVEL transmembrane domain containing 
6 (CMTM6) belongs to the CMTM family (CMTM1–8) and 
is expressed at the cell membrane of various types of cells (2). 
Recently, CMTM6 was identified as a master regulator of the 
PD-L1 protein. CMTM6 binds PD-L1 and maintains its cell sur-
face expression. In the absence of CMTM6, endocytosed PD-L1 
is rerouted for lysosomal degradation (3, 4). Only a few reports 
have investigated the clinical significance of CMTM6 expres-
sion in malignancies, including lung cancer and hepatocellular 
carcinoma (5-8). 
We aimed to clarify the significance of CMTM6 expression 
and analyze the relationship between CMTM6 and PD-L1 ex-
pression in patients with gastric cancer (GC).  
PATIENTS AND METHODS
Patients
A total of 105 patients who had undergone surgical resection 
for stage II / III gastric cancer at Tokushima University Hospi-
tal between 2006 and 2012 were included in this study (stage 
II / III : 42 / 63). Patients’ characteristics are shown in the Table 
1. The study included 75 men and 30 women, with a mean age 
of 67.8 years (range, 38–95 years). The mean follow-up period 
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Table 1.　Patients’ characteristics
Variables n = 105
Age 68 ± 13
Sex (Male / Female) 75 / 30
Differentiation (Dif  / Undif) 52 / 53
Number of Lymph node mets, N (≤ 5 / ≥ 6) 60 / 45
Type (1 / 2 / 3 / 4) 10 / 24 / 62 / 9
Location (U / M / L) 23 / 39 / 43
Tumor size (< 5 / ≥ 5 cm) 50 / 55
CEA (< 5 / ≥ 5 ng / ml) 91 / 14
CA19-9 (< 37 / ≥ 37 IU / ml) 81 / 24
DG / TG 54 / 51
Operative time (min) 298 ± 76
DG : distal gastrectomy, TG : total gastrectomy
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was 34 months (range, 7–87 months). Seventy-three patients 
had received adjuvant chemotherapy following standard guide-
lines. The characteristic factors were defined according to the 
15th edition of the Japanese Classification of Gastric Carcinoma 
published by the Japanese Gastric Cancer Association (9). This 
study was authorized in advance by the Institutional Review 
Board of Tokushima University, and all the patients provided 
written informed consent (No. 2901). These patients were also 
included in our previous study (1).
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed (8). The tissue samples were formalin-fixed and par-
affin-embedded. Serial sections were cut at 5-μm intervals, 
dewaxed, deparaffinized in xylene, and rehydrated through a 
series of graded alcohols. The samples were boiled for 20 min in 
a microwave oven in citrate buffer (pH 6.0) for antigen retrieval. 
Endogenous peroxidases were blocked with 0.3% hydrogen per-
oxidase for 30 min, followed by incubation in 5% goat serum for 
60 min to prevent nonspecific antigen binding. The slides were 
then incubated with primary antibodies overnight at 4°C. The 
following primary antibodies and dilutions were used : mouse 
monoclonal antibody for CMTM6 (1 : 100 ; Thermo Fisher Sci-
entific ; PA5-34744). Secondary antibody binding was detected 
using the Envision Dual Link System-HRP (DAKO). A second-
ary peroxidase-labeled polymer conjugated to goat anti-mouse 
immunoglobulins was applied for 60 min. The sections were 
developed in 3,3 -́diaminobenzidine and counterstained with 
Mayer’s hematoxylin. Each slide was dehydrated through grad-
ed alcohols and covered with a coverslip. The presence of positive 
cells on each slide was determined by a pathologist in a blinded 
manner. CMTM6 expression was predominantly located in the 
cytoplasm at the invasive front of the tumor. The staining inten-
sity was graded as follows : 0 = no staining, 1+ = weak staining, 
2+ = moderate staining and 3+ = strong staining. The propor-
tion scores were as follows : 0, none ; 1, <10% ; 2, 10%–50% ; 3, 
51%–80% ; 4, >80%. A total score greater than 4+ was defined 
as CMTM6-positive expression (Figure 1). Sixty-five patients 
(61.9%) were CMTM6 positive. We previously evaluated PD-L1 
expression in gastric cancer tissue (1). Correlation between the 
CMTM6 expression and PD-L1 expression were evaluated.
Statistical analysis
All statistical analyses were performed using JMP 8.0.1 sta-
tistical software (SAS, Cary, NC, USA). Continuous variables 
were compared using the Mann–Whitney U-test, and categori-
cal data were tested using χ2 test. Survival curves were calcu-
lated using the Kaplan–Meier method and were compared using 
the log-rank test. The prognostic potentials of the parameters 
were analyzed by univariate analysis. Relative risk and 95% 
confidence intervals (CI) were estimated using the Cox propor-
tional hazards model with stepwise forward selection. Statistical 
significance was defined as p < 0.05.
RESULTS
The characteristics of the CMTM6-positive and -negative 
groups are shown in Table 2. Regarding the clinicopathological 
variables, CMTM6 expression was not positively correlated with 
any clinicopathological factor investigated.  
The overall survival (OS) rates were significantly poorer 
in the CMTM6-positive group than in the CMTM6-negative 
group (5-year OS : 57.2% vs. 79.2%, respectively ; p < 0.05) (Fig-
ure 2a). Univariate analysis identified T factor, the number of 
positive lymph node metastases, the CA19-9 level, and CMTM6 
expression as significant prognostic factors for OS (p < 0.05). 
Multivariate analysis confirmed the number of positive lymph 
node metastases as an independent prognostic factor (relative 
risk : 2.44 ; p < 0.05). CMTM tended to be an independent prog-
nostic factor (relative risk : 2.47 ; p < 0.06) (Table 3).
Disease-free survival (DFS) was significantly poorer in the 
CMTM6-positive group than in the CMTM6-negative group 
(5-year DFS : 52.8% vs. 72.4%, respectively ; p < 0.05) (Figure 
2b). Univariate analysis identified that the number of positive 
lymph node metastases, CA19-9 level, and CMTM6 expression 
are significant prognostic factors for DFS (p < 0.05). Multivariate 
analysis confirmed that the number of positive lymph node me-
tastases and CMTM6 expression are independent risk factors for 
recurrence (p < 0.05) (Table 4). Additionally, both the CMTM6- 
and PD-L1-positive expression groups (n = 20) had a poorer prog-
nosis than the double-negative expression groups in OS (p < 0.05) 
(Figure 3a) and DFS (p < 0.05) (Figure 3b).
CMTM6 expression tended to be positively correlated with 
PD-L1 expression (p = 0.07) (Figure 4).
 Figure 1.　Immunohistochemistry of CMTM6 in gastric cancer tissue.
Table 2.　Characteristics of CMTM6-positive and CMTM6-negative 
patients
Variables Positive(n = 65)
Negative
(n = 40) p Value
Age 68 ± 12 67 ± 14 0.64
Sex (Male / Female) 42 / 23 33 / 7 0.06
Differentiation (Dif / Undif) 34 / 31 18 / 22 0.53
Number of Lymph node mets, 
N (≤ 5 / ≥ 6) 35 / 30 25/ / 15 0.38
Type (1 / 2 / 3 / 4) 3 / 16 / 40 / 6 7 / 8 / 22 / 3 0.14
Location (U / M / L) 14 / 26 / 25 9 / 13 / 18 0.56
Tumor size (< 5 / ≥ 5 cm) 27 / 38 23 / 17 0.09
CEA (< 5 / ≥ 5 ng/ml) 55 / 10 36 / 4 0.43
CA19-9 (< 37 / ≥ 37 IU/ml) 50 / 15 31 / 9 0.95
DG / TG 35 / 30 19 / 21 0.53
Operative time (min) 296 ± 80 300 ± 68 0.75
DG : distal gastrectomy, TG : total gastrectomy
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Figure 2.　Kaplan–Meier analysis of OS and DFS for CMTM6 (a, b).
2a 2b
Table 3.　Univariate and multivariate analysis for OS
Variables Univariate Multivariate
5-year OS rate (%) p-Value HR (95% CI) p-Value
Age in years (< 70 / ≥ 70) 71.5 / 61.2 0.17
Sex (Male / Female) 59.2 / 82.3 0.08 2.03 (0.67–6.13) 0.21
Dif / Undif 64.9 / 67.5 0.76
T 1–3 / 4 76.0 / 45.0 < 0.05 2.24 (0.98–5.13) 0.06
Number of Lymph node mets, N (≤ 5 / ≥ 6) 75.6 / 51.6 < 0.05 2.44 (1.05–5.65) < 0.05
fStage II / III 75.4 / 60.4 0.18
Tumor size (< 5 / ≥ 5 cm) 70.2 / 61.7 0.59
CEA (< 5 / ≥ 5 ng / ml) 68.9 / 58.4 0.19
CA19-9 (< 37 / ≥ 37 IU / ml) 74.2 / 45.0 < 0.05 2.47 (0.95–4.49) 0.11
DG / TG 68.8 / 63.0 0.68
CMTM6 (- / +) 79.2 / 57.2 < 0.05 2.47 (0.97–6.21) 0.06
DG : distal gastrectomy, TG : total gastrectomy
Table 4.　Univariate and multivariate analysis for DFS
Variables Univariate Multivariate
5-year OS rate (%) p-Value HR (95% CI) p-Value
Age in years (< 70 / ≥ 70) 69.4 / 48.3 0.08 1.65 (0.78–3.47) 0.19
Sex (Male / Female) 52.6 / 75.6 0.08 0.62 (0.29–1.60) 0.32
Dif / Undif 60.3 / 59.6 0.73
T 1–3 / 4 63.9 / 51.1 0.13
Number of Lymph node mets, (≤5 / ≥6) 71.6 / 41.3 < 0.05 2.43 (1.16–5.10) < 0.05
fStage II / III 68.1 / 53.7 0.14
Tumor size (< 5 / ≥ 5 cm) 65.5 / 49.9 0.18
CEA (< 5 / ≥ 5 ng/ml) 61.1 / 53.9 0.24
CA19-9 (< 37 / ≥ 37 IU/ml) 64.7 / 42.3 < 0.05 1.79 (0.86–3.73) 0.12
DG / TG 58.4 / 61.4 0.82
CMTM6 (- / + ) 72.4 / 52.8 < 0.05 2.22 (0.99–5.00) < 0.05
DG : distal gastrectomy, TG : total gastrectomy
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DISCUSSION
The results of this study demonstrated that CMTM6 expres-
sion is a marker for poor prognosis in terms of both OS and DFS, 
and CMTM6 expression tended to correlate with PD-L1 expres-
sion in patients with stage II / III gastric cancer after curative 
resection. 
CMTM comprises eight subtypes (CMTM1–8). CMTM shows 
broad-spectrum chemotactic activity and plays important roles 
in the hematopoietic, immune, cardiovascular, and male re-
productive systems (10-14). CMTM6 was identified as a master 
regulator of PD-L1 in 2017. CMTM6 directly or indirectly mod-
ifies one of the lysines in the PD-L1 cytoplasmic domain(3, 4). 
The T-cell inhibitory capacity of PD-L1-expressing tumor cells 
is enhanced by CMTM6. CMTM6 shows significant specificity 
for PD-L1. CMTM6 is a therapeutic target that enhances the 
effectiveness of current immunotherapy : PD-L1 / PD-1 blocking 
therapies (3, 4).
To our best knowledge, this is the first report concerning 
CMTM6 in GC. Only a few reports have investigated CMTM6 
in other solid malignancies (5-8). In lung adenocarcinoma, 
CMTM6 expression was positively correlated with PD-L1 in 
both the mRNA and protein levels. Furthermore, CMTM6 
expression was positively correlated with immune-infiltrating 
cells, resting dendritic cells, eosinophils, M1 or M2 macro-
phages, neutrophils, and CD4 T cells (5). Kan demonstrated that 
CMTM6 could predict the clinical response to PD-1 inhibitors 
(6). In hepatocellular carcinoma, the survival time of the pa-
tients was different between the CMTM6-positive and -negative 
groups. Additionally, the downregulation of CMTM6 is related 
to distant metastasis (7).
CMTM6 controls PD-L1 expression (3, 4). We previously 
reported PD-1 expression in gastric cancer patients and that 
PD-L1 expression or Indoleamine 2, 3-dioxygenase (IDO) cor-
related with a poor prognosis in gastric cancer after curative 
resection (1, 15). Furthermore, PD-1 expression was correlated 
3a 3b
Figure 3.　Kaplan–Meier analysis of OS and DFS for Survival for double CMTM6 and PD-L1 expression (a, b).
Figure 4.　Correlation between CMTM6 and PD-L1.
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with PD-L1 expression (1). The correlations between CMTM6 
and PD-1, IDO, FoxP3, and TGFβ were investigated in the pres-
ent study. However, no significant correlations were observed 
(data not shown). 
Immunogenic agents targeting T-cell immune checkpoints, 
such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated 
antigen-4, are currently being applied in the treatment of several 
types of cancers (16-18). Nivolumab was adapted for unresect-
able or recurrent GC. However, the Attraction 2 trial revealed a 
median overall survival of 5.26 months and a 12-month overall 
survival rate of 26.2% in the nivolumab group (19). Koh showed 
that CMTM6 is an independent predictor of the response to PD-1 
inhibitors. CMTM6 expression can be a promising predictor use-
ful for therapeutic decision-making regarding PD-1 inhibitors. 
(20)
In conclusion, CMTM6 expression is associated with a poor 
prognosis in patients with GC. Thus, CMTM6 expression may 
represent a useful new therapeutic target for GC treatment.
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